Despite soaring global demand for healthcare, the challenge of profitably developing treatments has never been greater or more ethically complex. Can pharma giants strike the right balance?
Recent insights
Investors Beware: Private Equity Firms Continue to Face Potential Liability Under the False Claims Act for Their Portfolio Companies’ Conduct
Two years ago, the U.S. Department of Justice announced a focus on enforcing the False Claims Act against private equity firms based on their portfolio …
Updates From ACI’s Advanced Forum on False Claims and Qui Tam Enforcement, June 22-23 in New York
Government, industry and outside counsel convened in New York June 22-23 at ACI’s Advanced Forum on False Claims and Qui Tam Enforcement to discuss …
First things first: Full Federal Court clarifies the law on patent term extensions
2022 Omnibus Spending Package Includes New Cybersecurity Incident Reporting Requirements for Critical Infrastructure Companies: How the Law May Affect Your Company
On March 15, 2022, President Joe Biden signed the Cyber Incident Reporting for Critical Infrastructure Act (the Act) into law as part of the $1.5 …
Will Trump-Appointed Justices Betray Their Stare Decisis Vow?
Litigation partner Michael J. Dell authored a RealClear Politics op-ed titled “Will Trump-Appointed Justices Betray Their Stare Decisis Vow?” …
Cyber-ransoms are on the rise: What do you need to know?
ACCC granted first interlocutory injunction to prevent merger in nearly 30 years
Climate change: succeed in a net-zero future
Digging Into FCA Stats: Part 3 – Litigation’s Return on Investment
Litigation associate Ralph C. Mayrell published this three-part series on the False Claims Act in Law360, Digging Into FCA Stats. Every year, the …
Digging Into FCA Stats: Part 2 – A Decade of Litigation Trends
Litigation associate Ralph C. Mayrell published this three-part series on the False Claims Act in Law360, Digging Into FCA Stats. Every year, the …
Digging Into FCA Stats: Part I – In-House Litigation Budget Insights
Litigation associate Ralph C. Mayrell published this three-part series on the False Claims Act in Law360, Digging Into FCA Stats. Every year, the …
FEDERAL COURT OVERTURNS ‘ABSURD’ PATENT OFFICE RULING ON PATENT TERM EXTENSIONS FOR PHARMACEUTICAL SUBSTANCES
Key contacts
Alan Montgomery
Partner, Head of Pharmaceuticals Sector, Chair of India Group, London
Chris Parker KC
Partner, Head of Pharmaceuticals Sector, London
Natalie Bryce
Partner, Brisbane